Interleukin-1 Receptor-Associated Kinase 4
IRAK4 is the central scaffold kinase that assembles the myddosome signaling complex downstream of all Toll-like receptors (TLR1-9 except TLR3) and all IL-1 family receptors. It drives innate immune responses through NF-κB and MAPK pathways. Critically, IRAK4 has both kinase-dependent and kinase-independent (scaffolding) functions — making it a uniquely compelling degradation target where inhibiting kinase activity alone is insufficient.
TLR/IL-1R ligation triggers recruitment of MyD88 adaptor protein, which oligomerizes and recruits IRAK4 via death domain interactions. IRAK4 auto-phosphorylates and phosphorylates IRAK1/2, triggering TRAF6 recruitment, K63-ubiquitin chain formation, TAK1 activation, and ultimate NF-κB/AP-1/IRF5 nuclear translocation and pro-inflammatory cytokine production (TNFα, IL-6, IL-8, IL-1β, IL-12, IL-18). IRAK4 also scaffolds the myddosome complex independently of kinase activity — making complete protein degradation far more effective than kinase inhibition.
IRAK4 kinase inhibitors (e.g., PF-06650833/Emfilerminib, BAY-1830839) showed efficacy in RA but were incomplete because IRAK4's scaffolding function persisted. The myddosome assembly still occurs when IRAK4 kinase is inhibited. Protein degradation eliminates both the kinase AND scaffolding functions simultaneously — a fundamental advantage over inhibitors. Kymera's predecessor KT-474 proved this concept in human Phase 1, demonstrating superior pathway suppression vs. kinase-only inhibition.
IRAK4 kinase inhibitors: PF-06650833/emfilerminib (Pfizer, Phase 2 in RA/IBD — showed partial efficacy), BAY-1830839 (Bayer, discontinued), M3258 (Merck KGaA, preclinical). None achieved full pathway blockade due to scaffolding function persistence.
pChEMBL = −log₁₀(IC₅₀). Higher value = more potent. Dashed line = 100 nM threshold. Showing top binding compounds in ChEMBL (31,578 total activities).
2nd-generation IRAK4 degrader designed with superior potency and CNS selectivity vs. first-gen KT-474. Predecessor KT-474 completed Phase 1 in healthy volunteers and patients with HS and AD, providing proof-of-concept for IRAK4 degradation as a therapeutic mechanism in humans. Sanofi is sponsoring and leading Phase 2 development.
KT-474 Phase 1 (2022): Proof-of-concept in atopic dermatitis patients. Deep IRAK4 degradation observed in PBMCs. Reductions in inflammatory cytokines (TNFα, IL-6, IL-8). Favorable safety profile.
No other company has a targeted protein degrader program against IRAK4 in the clinic. Kymera holds first-mover advantage in this target.
≥75% reduction in total abscess and nodule count (AN) with no increase in draining tunnels or abscesses. Primary endpoint for HS trials.
Score of 0 (clear) or 1 (almost clear) with ≥2-point improvement from baseline. Key secondary in HS.
Standard RA primary endpoints. ACR50/70 are increasingly preferred in trials.
Composite RA disease activity measure using 28 joint counts plus CRP.
Total patient potential: Broad immune-inflammatory populations: HS (~3M US), AD (~16M US), RA (~1.3M US), IBD (~3M US)